DOS47 is designed to offer a means of deriving a therapeutic pharmacological effect by action upon a naturally occurring substance in the body. The technology is based on the principle of using an enzyme to catalyse the metabolism catabolism of and endogenous substrate molecule in order to yield metabolites of therapeutic benefit.

Specifically cancer generally share a common trait° they exist and propagate under conditions of abnormally low interstitial pH high acidity DOS47 is designed to induce an increase in pH locally at the site of cancerous cells in the body to create an environment inhospitable to their continued growth and survival.

Specifically cancer generally share a common trait° they exist and propagate under conditions of abnormally low interstitial pH high acidity DOS47 is designed to induce an increase in pH locally at the site of cancerous cells in the body to create an environment inhospitable to their continued growth and survival.

Helix's granted US patents provide protection for both of these possible therapeutic applications Helix envisions applying its DOS47 technology to multiple different solid tumor types by combining it with cancer specific targeting agents able to localize potent DOS47 therapy to any given tumor target in the body Helix's first DOS47 based targeted therapeutic under development LDOS47 is a potential treatment for inoperable locally advanced recurrent or metastatic non small cell lung cancer NSCLC.

pending the identification of further tumor targeting agents like the lung adenocarcinoma antibody component of LDOS47